Pioneering Rosalind study aims to transform cancer treatment with insights from ‘super-responder’ patients Tumor samples from over 1,000 cancer survivors across three aggressive types will be analyzed ...

In the ever-evolving landscape of pharmaceutical research and development, the demand for innovative and efficient drug discovery methods is more pressing than ever. At the forefront of this demanding ...

ABPI has today (Monday) welcomed a new report from The King’s Fund which explores the positive impacts of NHS and industry partnerships.

BrightHeart, a leading AI innovator in obstetric and pediatric cardiology technology, announces it has received FDA 510(k) clearance for its first artificial intelligence software, designed to ...

Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announces that AstraZeneca has ...

ICR Healthcare, a leading global strategic communication, investor relations and capital markets advisory firm specializing in the healthcare sector, today hosts its 12th Annual Healthcare Conference: ...

After successful sandpit events in Liverpool and London earlier this year, iiCON (Infection Innovation Consortium) is excited to announce 11 new projects during World AMR Awareness Week. These ...

Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines, wishes to provide an update on its ...

CD Formulation, a leading contract research and development biotechnology firm, highlights the critical importance of compatibility studies between drug formulations and their respective packaging ...

Research Nester’s recent market research analysis on “Patient Engagement Solutions Market: Global Demand Analysis & Opportunity Outlook 2037” delivers a detailed competitor’s analysis and a detailed ...

Statement/Regulatory AdmissionFormycon receives positive CHMP opinion for FYB203 (aflibercept), a biosimilar candidate to Eylea® under the tradenames AHZANTIVE® and Baiama® 18.11.2024 / 06:30 ...

LONDON, UNITED KINGDOM / ACCESSWIRE / November 18, 2024 / Nanomerics Ltd., a private speciality pharmaceutical company announced that it had received clinical trials authorisation for its first in ...